Results 151 to 160 of about 6,869 (208)

Multicenter surveillance of antifungal susceptibility of clinical <i>Aspergillus</i> isolates to conventional and novel antifungal agents in Taiwan, 2021-2023. [PDF]

Microbiol Spectr
Hsieh M, Choi P-C, Wu W-L, Lin Y-F, Wu C-J.   +4 more
europepmc   +1 more source

CYP51C Y319H and H349R substitutions cannot confer azole resistance in <i>Aspergillus flavus</i> NRRL 3357-5. [PDF]

Microbiol Spectr
Zhou YB, Grum-Grzhimaylo AA, Meijer M, Kraak B, Houbraken J.   +4 more
europepmc   +1 more source

Ergosterol-depleted clinical isolates of <i>Nakaseomyces glabratus</i> can develop multi-drug resistance without severe fitness defects or attenuated virulence in an invertebrate infection model. [PDF]

mBio
Aldejohann AM, Thielemann N, Martinez Zurita A, Müller C, Gräfenhan T, Kriz R, Lagler H, Behr IS, Reus N, Schöninger A, Walther G, Mazan L-M, Wilhelm H, Willinger B, Cuomo CA, Kurzai O, Martin R.   +16 more
europepmc   +1 more source

Beyond <i>Candida</i>: Epidemiological Insights into Rare Yeast Fungaemia in Greece from a 15-Year Hospital-Based Study and Literature Review. [PDF]

J Fungi (Basel)
Siopi M, Mitsopoulos D, Alevra A, Vargiami M, Pournaras S, Meletiadis J.   +5 more
europepmc   +1 more source

Deciphering the multidrug resistance paradigm in <i>Candida auris</i>. [PDF]

Antimicrob Agents Chemother
Santana DJ, Cauldron NC, Rogers PD, Cuomo CA.   +3 more
europepmc   +1 more source

Anidulafungin, a New Echinocandin

Drugs, 2009
Anidulafungin is a new echinocandin with potent in vitro activity against Aspergillus and Candida species, including those resistant to fluconazole and amphotericin B. Results of several clinical trials indicate that anidulafungin is effective in treating oesophageal candidiasis, including azole-refractory disease.
G. Morace, E. Borghi, R. Iatta, M. T. Montagna   +3 more
core   +8 more sources

Some of the next articles are maybe not open access.

Related searches:

Anidulafungin: an echinocandin antifungal

Expert Opinion on Investigational Drugs, 2004
Anidulafungin (LY-303366, V-echinocandin trade mark, Vicuron Pharmaceuticals, Inc.) is a new echinocandin antifungal agent with broad spectrum activity against Candida and Aspergillus spp. Anidulafungin exhibits low toxicity, concentration-dependent fungicidal activity for Candida, and a prolonged post antifungal effect (> 12h).
exaly   +3 more sources

Anidulafungin

Drugs, 2004
Anidulafungin is a novel antifungal agent which, like other echinocandins, inhibits beta-(1,3)-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against a broad spectrum of Candida spp. and Aspergillus spp., including amphotericin B- and triazole-resistant strains.
David, Murdoch, Greg L, Plosker
  +5 more sources